Suppression of Coronary Atherosclerosis by Helix B Surface Peptide, a Nonerythropoietic, Tissue-Protective Compound Derived from Erythropoietin
Tóm tắt
Erythropoietin (EPO), a type I cytokine originally identified for its critical role in hematopoiesis, has been shown to have non-hematopoietic, tissue-protective effects, including suppression of atherosclerosis. However, prothrombotic effects of EPO hinder its potential clinical use in nonanemic patients. In the present study, we investigated the antiatherosclerotic effects of helix B surface peptide (HBSP), a nonerythropoietic, tissue-protective compound derived from EPO, by using human umbilical vein endothelial cells (HUVECs) and human monocytic THP-1 cells in vitro and Watanabe heritable hyperlipidemic spontaneous myocardial infarction (WHHLMI) rabbits in vivo. In HUVECs, HBSP inhibited apoptosis (≈70%) induced by C-reactive protein (CRP), a direct mediator of atherosclerosis. By using a small interfering RNA approach, Akt was shown to be a key molecule in HBSP-mediated prevention of apoptosis. HBSP also attenuated CRP-induced production of tumor necrosis factor (TNF)-α and matrix metalloproteinase-9 in THP-1 cells. In the WHHLMI rabbit, HBSP significantly suppressed progression of coronary atherosclerotic lesions as assessed by mean cross-sectional stenosis (HBSP 21.3 ± 2.2% versus control peptide 38.0 ± 2.7%) and inhibited coronary artery endothelial cell apoptosis with increased activation of Akt. Furthermore, TNF-α expression and the number of M1 macrophages and M1/M2 macrophage ratio in coronary atherosclerotic lesions were markedly reduced in HBSP-treated animals. In conclusion, these data demonstrate that HBSP suppresses coronary atherosclerosis, in part by inhibiting endothelial cell apoptosis through activation of Akt and in association with decreased TNF-α production and modified macrophage polarization in coronary atherosclerotic lesions. Because HBSP does not have the prothrombotic effects of EPO, our study may provide a novel therapeutic strategy that prevents progression of coronary artery disease.
Tài liệu tham khảo
Jelkmann W. (2007) Erythropoietin after a century of research: younger than ever. Eur. J. Haematol. 78:183–205.
Brines M, Cerami A. (2008) Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J. Intern. Med. 264:405–32.
Buemi M, et al. (1998) Does erythropoietin administration affect progression of atherosclerosis in Watanabe heritable hyperlipaemic rabbits? Nephrol. Dial. Trans-plant. 13:2706–8.
Pawlak K, Pawlak D, Mysliwiec M. (2006) Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patients. Am. J. Nephrol. 26:497–502.
Siamopoulos KC, et al. (2006) Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD. Am. J. Kidney Dis. 48:242–9.
Lu KY, et al. (2010) Erythropoietin suppresses the formation of macrophage foam cells: role of liver X receptor alpha. Circulation. 121:1828–37.
Brines M, et al. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U. S. A. 101:14907–12.
Khorana AA, Francis CW, Culakova E, Lyman GH. (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 104:2822–9.
Corwin HL, et al. (2007) Efficacy and safety of epoetin alfa in critically ill patients. N. Engl. J. Med. 357:965–76.
Aapro M, Scherhag A, Burger HU. (2008) Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br. J. Cancer. 99:14–22.
Brines M, et al. (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. U. S. A. 105:10925–30.
Erbayraktar Z, Erbayraktar S, Yilmaz O, Cerami A, Coleman T, Brines M. (2009) Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. Mol. Med. 15:235–41.
Ueba H, et al. (2010) Cardioprotection by a non-erythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc. Natl. Acad. Sci. U. S. A. 107:14357–62.
Ahmet I, et al. (2011) A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol. Med. 17:194–200.
Shiomi M, Ito T, Yamada S, Kawashima S, Fan J. (2003) Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). Arterioscler. Thromb. Vasc. Biol. 23:1239–44.
Nabata A, et al. (2008) C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: implications for the destabilization of atherosclerotic plaque. Atherosclerosis. 196:129–35.
Ueba H, et al. (2005) Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis. 183:35–9.
Shiomi M, Ito T, Hirouchi Y, Enomoto M. (2001) Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis 157:75–84.
Khreiss T, Jozsef L, Potempa LA, Filep JG. (2004) Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation. 109:2016–22.
Verma S, Szmitko PE, Ridker PM. (2005) C-reac-tive protein comes of age. Nat. Clin. Pract. Cardiovasc. Med. 2:29–36.
Pepys MB, et al. (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 440:1217–21.
Calvillo L, et al. (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. U. S. A. 100:4802–6.
Fiordaliso F, et al. (2005) A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 102:2046–51.
Salahudeen AK, et al. (2008) Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am. J. Physiol. Renal Physiol. 294:F1354–65.
Agnello D, et al. (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 952:128–34.
Villa P, et al. (2003) Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med. 198:971–5.
Valgimigli M, et al. (2003) Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Arch. Biochem. Biophys. 420:255–61.
McKellar GE, McCarey DW, Sattar N, McInnes IB. (2009) Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat. Rev. Cardiol. 6:410–7.
de Nooijer R, et al. (2006) Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler. Thromb. Vasc. Biol. 26:340–6.
Siren AL, et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U. S. A. 98:4044–9.
Bittorf T, Buchse T, Sasse T, Jaster R, Brock J. (2001) Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance. Cell Signal. 13:673–81.
Parsa CJ, et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 112:999–1007.
Watanabe Y, et al. (1988) Preventive effect of pravastatin sodium, a potent inhibitor of 3-hy-droxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim. Biophys. Acta. 960:294–302.
Chinetti-Gbaguidi G, Staels B. (2011) Macrophage polarization in metabolic disorders: functions and regulation. Curr. Opin. Lipidol 22:365–72.